MedTrace Logo

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis

NCT05121870 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2021-11-16

No results posted yet for this study

Summary

Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.

Conditions

  • Decompensated Cirrhosis

Interventions

BIOLOGICAL

UC-MSCs

3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.

BIOLOGICAL

Saline containing 1% Human serum albumin（solution without UC-MSCs）

3 does of placebo intravenously at week 0, week 4, week 8.

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • LanZhou University

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Vcanbio Cell and Gene Engineering Corp., Ltd.

    collaborator INDUSTRY

  • Beijing 302 Hospital

    lead OTHER

Principal Investigators

  • Fu-Sheng Wang, MD, PhD · Beijing 302 Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121870 on ClinicalTrials.gov